Cochlear Americas appears in FDA premarket approval records as the applicant for a set of Class 3 ear, nose, and throat devices spanning auditory brainstem and cochlear implants. The supplied collection holds ten linked PMA records as of November 20, 2026, split evenly between five OK30 decisions and five APPR decisions. The five records sampled in detail are all 30-Day Notices decided September 28, 2026, each received August 31, 2026, and each tied to the same manufacturing change. [1][2][5]
Documented device families
The filings name four distinct systems. P000015 covers the Cochlear Auditory Brainstem Implant System, listed under product code MHE with the generic name Implant, auditory brainstem. P890027 and P840024 both cover the Nucleus® 22 Cochlear Implant System, while P970051 covers the Nucleus® 24 Cochlear Implant System; all three fall under product code MCM and the generic name Implant, cochlear. P130016 covers the Cochlear Hybrid Implant System, product code PGQ, described generically as a cochlear implant with combined electrical stimulation and acoustic amplification. [1][2][3][4][5]
Each sampled record lists the applicant as Cochlear Americas at 10350 Park Meadows Dr., Lone Tree, Colorado, and assigns the Ear, Nose, Throat advisory committee. That address is a filing address in the FDA record; the sources do not establish a corporate headquarters, parent company, or brand ownership, so those remain unknown. [1][3][5]
The September 2026 supplements
All five sampled supplements share one scope statement: a change to the joining process in the manufacturing of the NEUF Child Lock component in Cochlear Sound Processors. The supplement reason is recorded as Process Change - Manufacturer/Sterilizer/Packager/Supplier, and each is classified as a 30-Day Notice rather than a panel-track or expedited review; the expedited review flag is N on every sampled record. [1][2][4]
The identifiers and dates are specific: P000015/S057, P890027/S067, P970051/S244, P840024/S099, and P130016/S061, each received August 31, 2026, and decided September 28, 2026, under decision code OK30. Because the change concerns a sound processor component, the supplements reach across implant families rather than a single device line. [2][3][4][5]
Reading the collection counts
The ten-record collection count of five OK30 and five APPR decisions describes the supplied filings only, as of the snapshot date. The five OK30 entries are the smaller recordSample, and the sample counts should not be read as the full collection's decision mix. Neither figure represents total company sales, total portfolio size, or safety performance, and the sources include no recall records. [1][2][3]
The remaining five APPR decisions are counted but not described in the numbered sources, so their devices, dates, and scope are unknown here. FDA's public PMA pages for P000015 and P890027S064 note that a supplement may have changed the device description, function, or indication from the original approval, which limits what a supplement record alone can say about a device's current labeling. [6][9][10]
What the record does not establish
The sources document regulatory filings, not clinical performance. They contain no effectiveness data, patient-selection criteria, or treatment guidance, and nothing indicates commercial availability, certifications, customers, or firsthand testing. Establishment registration and device listing pages for product code MCM appear among the sources but supply only page navigation text, so they add no verified facility detail. [7][8]






